How should hormonally driven pseudoangiomatous stromal hyperplasia (PASH) be managed?

Management of Hormonally Driven Pseudoangiomatous Stromal Hyperplasia (PASH)

For hormonally driven PASH, observation with clinical and radiologic surveillance at 6-month intervals is the preferred initial approach for small, asymptomatic lesions confirmed by core needle biopsy, while surgical excision is reserved for lesions >3 cm, progressive growth, or suspicious imaging features. 1, 2

Initial Diagnostic Approach

Core needle biopsy is sufficient to confirm PASH when imaging or physical examination findings are abnormal, eliminating the need for routine surgical excision to rule out occult malignancy. 1 The diagnosis can be established on core biopsy in approximately 64-65% of cases, though 35% may require surgical excision for definitive diagnosis when core biopsy is inconclusive. 3, 2

Key Diagnostic Features:

• PASH predominantly affects premenopausal and perimenopausal women (96% of cases), with median age around 41 years. 3, 1
• Lesions typically present as palpable masses (56%) or imaging-detected abnormalities. 2
• Mammography and ultrasonography findings are nonspecific and cannot distinguish PASH from other benign lesions. 3, 4
• Immunohistochemistry reveals 95% of PASH lesions are estrogen or progesterone receptor positive, confirming the hormonal basis for development. 3

Treatment Algorithm Based on Clinical Presentation

For Small, Asymptomatic Lesions (<3 cm):

• Observation with clinical examination and imaging surveillance every 6 months is appropriate when PASH is confirmed on core needle biopsy without suspicious radiologic features. 1, 2
• This conservative approach avoids unnecessary surgical morbidity in patients with incidentally detected lesions. 4

Indications for Surgical Excision:

• Lesions >3 cm in size 1
• Progressive growth or enlargement of palpable mass 1
• Suspicious imaging findings that cannot be definitively characterized 1, 2
• Inconclusive or negative core biopsy results 2
• Synchronous lesions requiring excision 4
• Patient preference or anxiety regarding observation 3

Hormonal Considerations

The strong hormonal responsiveness of PASH has important management implications:

• PASH occurs almost exclusively in premenopausal/perimenopausal women, with rare cases in men associated with gynecomastia or exogenous hormone use. 3
• Progesterone receptor expression typically exceeds estrogen receptor expression in stromal cells. 5
• The pathogenesis likely involves aberrant myofibroblast reactivity to endogenous or exogenous hormones. 5

However, there is no established role for hormonal manipulation (such as aromatase inhibitors or anti-estrogen therapy) in the management of PASH, as the evidence base consists only of observational studies without therapeutic trials. 3, 1, 4, 2, 5

Recurrence and Long-Term Management

• Recurrence rates range from 13-26%, with higher rates (26%) in the observation arm versus 13% in the excision arm. 2
• Five of 40 patients (12.5%) experienced ipsilateral recurrences in one series, with two developing contralateral PASH. 5
• Simple excision is adequate treatment for initial presentation and infrequent recurrences. 5
• Diffuse or bilateral PASH presenting a management challenge may rarely necessitate mastectomy, though this is exceptional. 5

Critical Pitfalls to Avoid

PASH is associated with concurrent breast cancer or carcinoma in situ in 30% of cases at or before diagnosis, necessitating thorough evaluation of the entire breast rather than focusing solely on the PASH lesion. 2 This high rate of synchronous pathology underscores the importance of:

• Complete imaging evaluation of both breasts
• Careful pathologic review of all tissue
• Appropriate biopsy of any additional suspicious lesions
• Not assuming PASH explains all clinical or radiologic findings

PASH itself carries no increased risk for malignant transformation and has an excellent prognosis, but the high rate of concurrent pathology requires vigilance. 4

Surveillance Protocol

For patients managed conservatively:

• Clinical examination and imaging at 6-month intervals initially 2
• Longer intervals may be appropriate after demonstrating stability over 1-2 years
• Immediate evaluation for any new palpable changes or imaging abnormalities
• Low threshold for excision if growth is documented